# 2025年12月11日 - 专业文献速递

本期速递为您整理了最新的科研文献及AI评价，每一篇文献都包含了详细的元数据、原文摘要、中文翻译和AI的专业点评，敬请参考。

---

## 1. 急性低氧性呼吸衰竭和脓毒症患者的数字孪生模型提示双水平高流量鼻导管治疗的潜在益处。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41369730)
**期刊：** Intensive care medicine
**PMID：** 41369730
**DOI：** 10.1007/s00134-025-08172-w

### 第一部分 原文与翻译

**英文原标题：** Digital twins of acute hypoxemic respiratory failure and sepsis patients suggest potential benefits of bi-level high flow nasal cannula therapy.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 无摘要可用。

### 第二部分 AI 大师评价

该研究利用数字孪生技术对急性低氧性呼吸衰竭及脓毒症患者进行模拟分析，探索双水平高流量鼻导管治疗的潜在临床优势。数字孪生模型可用于在虚拟环境中检验干预策略，为重症监护领域提供数据驱动的新视角。尽管实际摘要缺失，但从标题推测，其创新点在于将精准模拟与临床呼吸支持策略相结合，为复杂病情的个体化治疗提供可能。主要局限在于模型假设与真实生理状态之间仍需进一步验证。

---

## 2. 氯胺酮与依托咪酯用于危重成人气管插管的比较研究

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41369227)
**期刊：** The New England journal of medicine
**PMID：** 41369227
**DOI：** 10.1056/NEJMoa2511420

### 第一部分 原文与翻译

**英文原标题：** Ketamine or Etomidate for Tracheal Intubation of Critically Ill Adults.

> **英文摘要：**
> BACKGROUND: For critically ill adults undergoing tracheal intubation, observational studies suggest that the use of etomidate to induce anesthesia may increase the risk of death. Whether the use of ketamine rather than etomidate decreases the risk of death is uncertain.
> 
> METHODS: In a randomized trial conducted in 14 emergency departments and intensive care units in the United States, we randomly assigned critically ill adults who were undergoing tracheal intubation to receive ketamine or etomidate for the induction of anesthesia. The primary outcome was in-hospital death from any cause by day 28. The secondary outcome was cardiovascular collapse during intubation, defined by the occurrence of a systolic blood pressure below 65 mm Hg, receipt of a new or increased dose of vasopressors, or cardiac arrest.
> 
> RESULTS: A total of 2365 patients underwent randomization and were included in the trial population; 1176 were assigned to the ketamine group and 1189 to the etomidate group. In-hospital death by day 28 occurred in 330 of 1173 patients (28.1%) in the ketamine group and in 345 of 1186 patients (29.1%) in the etomidate group (risk difference adjusted for trial site, -0.8 percentage points; 95% confidence interval [CI], -4.5 to 2.9; P = 0.65). Cardiovascular collapse during intubation occurred in 260 of 1176 patients (22.1%) in the ketamine group and in 202 of 1189 patients (17.0%) in the etomidate group (risk difference, 5.1 percentage points; 95% CI, 1.9 to 8.3). Prespecified safety outcomes were similar in the two groups.
> 
> CONCLUSIONS: Among critically ill adults undergoing tracheal intubation, the use of ketamine to induce anesthesia did not result in a significantly lower incidence of in-hospital death by day 28 than etomidate. (Funded by the Patient-Centered Outcomes Research Institute and others; RSI ClinicalTrials.gov number, NCT05277896.).

> **中文摘要：**
> 背景：对接受气管插管的危重成人而言，观察性研究提示使用依托咪酯诱导麻醉可能增加死亡风险。目前尚不确定使用氯胺酮而非依托咪酯是否能降低死亡风险。
> 
> 方法：在美国14家急诊科和重症监护病房开展了一项随机对照试验，我们随机分配接受气管插管的危重成人，在麻醉诱导时分别使用氯胺酮或依托咪酯。主要结局为28天内任何原因导致的住院死亡。次要结局为插管期间的心血管崩溃，定义为收缩压低于65 mmHg、需要新使用或增加升压药剂量，或发生心脏骤停。
> 
> 结果：共有2365名患者被随机分配并纳入试验总体，其中1176例接受氯胺酮，1189例接受依托咪酯。至第28天时，氯胺酮组1173例中有330例（28.1%）死亡，依托咪酯组1186例中有345例（29.1%）死亡，经试验中心调整的风险差为-0.8个百分点（95%置信区间，-4.5至2.9；P＝0.65）。插管期间的心血管崩溃发生于氯胺酮组260例（22.1%）和依托咪酯组202例（17.0%），风险差为5.1个百分点（95%置信区间，1.9至8.3）。预先设定的安全性结局在两组间相似。
> 
> 结论：在接受气管插管的危重成人中，使用氯胺酮进行麻醉诱导与使用依托咪酯相比，并未显著降低28天内住院死亡率。（由以患者为中心的结果研究所及其他机构资助；RSI临床试验注册号：NCT05277896。）

### 第二部分 AI 大师评价

本研究为一项多中心随机对照试验，旨在比较氯胺酮与依托咪酯在危重成人气管插管时的死亡率和心血管反应差异。研究结果显示，两种药物在28天住院死亡率上的差异无统计学意义，但氯胺酮组心血管崩溃的发生率略高。该研究提供了高质量的循证依据，对临床药物选择具有实际指导意义。然而研究的局限性包括特定人群和操作环境可能影响结果外推性。

---

## 3. 早产儿初始复苏的靶向氧策略：TORPIDO 30/60 随机临床试验

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41369162)
**期刊：** JAMA
**PMID：** 41369162
**DOI：** 10.1001/jama.2025.23327

### 第一部分 原文与翻译

**英文原标题：** Targeted Oxygen for Initial Resuscitation of Preterm Infants: The TORPIDO 30/60 Randomized Clinical Trial.

> **英文摘要：**
> IMPORTANCE: The most effective initial fraction of inspired oxygen (Fio2) for resuscitating preterm newborns is unknown.
> 
> OBJECTIVE: To compare outcomes of newborns born at 23 to 28 weeks' gestation resuscitated with initial Fio2 of 0.6 vs 0.3.
> 
> DESIGN, SETTING, AND PARTICIPANTS: Randomized clinical trial conducted in 31 maternity hospitals in 6 countries. Consent by waiver was obtained in Australia, certain institutions in India, and Malaysia; prospective informed consent was obtained in certain institutions in India and all institutions in Singapore, Spain, and the US. Infants due at 23 to 28 weeks' gestation were randomized shortly before birth. Those with congenital abnormalities affecting oxygenation, neurodevelopment, or survival were excluded. Randomization was conducted from September 2018 to September 2024, with follow-up expected to close in September 2026.
> 
> INTERVENTION: Infants were randomized (1:1) to receive an initial Fio2 of 0.6 or 0.3; Fio2 was titrated to meet standard targets for oxygen saturation by pulse oximetry in the first 10 minutes or for clinical needs. Clinicians and those assessing outcomes were not blinded to group assignment.
> 
> MAIN OUTCOMES AND MEASURES: The primary outcome was death and brain injury at 36 weeks' corrected gestational age; secondary outcomes were the individual components of the primary outcome.
> 
> RESULTS: A total of 1641 newborns were randomized. The primary analysis included 728 newborns randomized to receive an Fio2 of 0.6 and 741 to an Fio2 of 0.3 after excluding 172 newborns, mostly for birth after 28 weeks' gestation and transfer to another hospital before birth (54% female). Rates of escalation to Fio2 of 1.0 were similar between the groups (Fio2 of 0.6: 41%; Fio2 of 0.3: 38%). Primary outcome information was ascertained in 1423 newborns (96.9%). Death or brain injury at 36 weeks' corrected gestational age occurred in 330 of 703 newborns (46.9%) assigned to the Fio2 of 0.6 group vs 344 of 720 (47.8%) assigned to the Fio2 of 0.3 group (relative risk, 0.98 [95% CI, 0.89-1.09]).
> 
> CONCLUSIONS AND RELEVANCE: Initiating resuscitation of preterm infants with Fio2 of 0.6 vs 0.3 did not affect the risk of death or brain injury by 36 weeks' corrected gestational age. These results lay a foundation for future trials evaluating the effectiveness and safety of using higher initial Fio2 levels for preterm infant resuscitation.
> 
> TRIAL REGISTRATION: ANZCTR Identifier: ACTRN12618000879268.

> **中文摘要：**
> 【重要性】目前尚不清楚用于复苏早产新生儿的最有效初始吸入氧分数（Fio2）。
> 
> 【目的】比较在孕周 23 至 28 周出生的新生儿分别以初始 Fio2 为 0.6 与 0.3 进行复苏后的结局差异。
> 
> 【设计、地点与参与者】这是一项在 6 个国家的 31 家产科医院中开展的随机临床试验。在澳大利亚、印度部分机构及马来西亚采用豁免知情同意；在印度部分机构及新加坡、西班牙和美国的所有机构采用前瞻性知情同意。孕周 23 至 28 周待产的婴儿在出生前不久被随机分组。排除了存在影响氧合、神经发育或生存的先天异常者。随机化从 2018 年 9 月持续至 2024 年 9 月，预计随访至 2026 年 9 月结束。
> 
> 【干预措施】婴儿按 1:1 比例随机分配接受初始 Fio2 为 0.6 或 0.3 的复苏；Fio2 根据脉搏血氧监测在出生后前 10 分钟内的氧饱和度标准目标或临床需求进行调节。临床医生及结局评估者对分组情况并非盲法。
> 
> 【主要结局与测量指标】主要结局为 36 周校正胎龄时的死亡或脑损伤；次要结局为主要结局的各组成部分。
> 
> 【结果】共 1641 名新生儿被随机分组。排除 172 名（主要因超过 28 周分娩或出生前转至他院）后，主要分析包括接受 Fio2 0.6 的 728 名及接受 Fio2 0.3 的 741 名（女性占 54%）。两组上调至 Fio2 1.0 的比例相似（Fio2 0.6 组：41%；Fio2 0.3 组：38%）。共有 1423 名新生儿（96.9%）可获取主要结局信息。在 36 周校正胎龄时，Fio2 0.6 组中 703 名婴儿中有 330 名（46.9%）死亡或发生脑损伤，Fio2 0.3 组中 720 名婴儿中有 344 名（47.8%）发生相同结局（相对风险 0.98，95% 置信区间 0.89–1.09）。
> 
> 【结论与意义】以初始 Fio2 为 0.6 与 0.3 开始复苏早产儿，在 36 周校正胎龄时的死亡或脑损伤风险无显著差异。该研究为未来探讨较高初始 Fio2 水平用于早产儿复苏的有效性与安全性奠定了基础。
> 
> 【试验注册】ANZCTR 标识号：ACTRN12618000879268。

### 第二部分 AI 大师评价

本研究是一项多国多中心随机临床试验，比较早产儿在复苏时采用初始 Fio2 为 0.6 或 0.3 的结局差异。结果显示，两种初始氧浓度在死亡及脑损伤风险方面无显著差异，提示常规使用较高氧浓度并不能带来额外益处。研究设计严谨、样本量大，为制定早产儿复苏氧策略提供了重要循证依据。其局限在于操作者与评估者未盲法，且仅覆盖 23–28 周人群，需进一步研究不同氧浓度策略的长期神经发育影响。

---

## 4. 重度脑损伤患者在重症监护病房中出现认知运动分离时物理及作业治疗的频率：一项回顾性队列研究

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41366454)
**期刊：** Critical care (London, England)
**PMID：** 41366454
**DOI：** 10.1186/s13054-025-05767-z

### 第一部分 原文与翻译

**英文原标题：** Frequency of physical and occupational therapy in the ICU for patients with cognitive motor dissociation: a retrospective cohort study.

> **英文摘要：**
> BACKGROUND: Supportive care is the primary focus of ICU management for unconscious patients early after severe acute brain injury. While benefits of early physical and occupational therapy are generally recognized, it remains uncertain how early therapy can begin and what patients most benefit form intensive, early therapy. Brain activation to motor commands detected by EEG also known as cognitive motor dissociation (CMD) is a predictor of recovery seen in up to 25% of patients. The purpose of this study was to determine if CMD patients that undergo early, intense physical and occupational therapy are particularly responsive to the treatment.
> 
> METHODS: In this retrospective analysis of prospectively collected data from 119 ICU patients with acute, severe brain injury who were assessed using the Coma Recovery Scale-Revised (CRS-R). CMD was detected applying machine learning to EEG recorded during verbal command presentation. Time from admission, type, and frequency of physical/occupational therapy, and pre-defined adverse events were recorded. Glasgow Outcome Scale-Extended (GOS-E) at discharge, 3, 6, and 12 months were the primary outcome. Investigators were blinded to CMD status. Outcomes were compared in relation to CMD status and therapy characteristics applying Wilcoxon signed-rank tests and ordinal regression.
> 
> RESULTS: CMD was detected in 16 (13%) patients and not associated with demographics or clinical factors. No therapy-related complications were observed. Between admission and discharge, GCS improved for all patients. Median delta GCS was the highest for CMD patients who received high-frequency therapy (OR 4.1 [1.1-16.3], p = 0.03). GOS-E was 4 or above in 26 (26%) by 12 months after the injury. CMD patients who received high-frequency therapy had larger increases in GOS-E at 6 and 12 months after discharge compared to those without CMD and those who did not receive frequency therapy (OR 10.7 [2.5,48.8] p = 0.001).
> 
> CONCLUSIONS: Physical and occupational therapy can be applied in the ICU using a safety protocol and CMD patients may be particularly responsive to early, intense therapy. Multicenter trials integrating CMD status should determine optimal timing and dosage of rehabilitation to support the allocation of this limited resource.

> **中文摘要：**
> 背景：对于严重急性脑损伤后早期处于昏迷状态的患者，重症监护病房（ICU）管理的主要目标是支持性治疗。尽管早期物理治疗和作业治疗的益处已被普遍认可，但仍不清楚治疗应在何时开始以及哪些患者最能从强化的早期治疗中获益。通过脑电图（EEG）检测到的对运动指令的脑激活（即所谓的认知运动分离，CMD）是一个恢复预后指标，可见于多达25%的患者。本研究旨在确定那些接受早期、高强度物理及作业治疗的CMD患者是否对治疗具备特别敏感的反应。
> 
> 方法：本研究为一项回顾性分析，使用前瞻性收集的119例ICU重度急性脑损伤患者的数据。这些患者接受了昏迷恢复量表修订版（CRS-R）的评估。CMD的检测通过对在语言指令呈现期间采集的EEG数据应用机器学习方法实现。记录了从入院起的时间、物理/作业治疗的类型与频率，以及预先定义的不良事件。主要结局为出院时及伤后3、6、12个月的格拉斯哥预后量表扩展版（GOS-E）评分。研究者对CMD状态保持盲法。采用Wilcoxon符号秩检验和有序回归分析CMD状态与治疗特征相关的结局差异。
> 
> 结果：在16例（13%）患者中检测到CMD，其发生与人口学或临床特征无关。未观察到与治疗相关的并发症。从入院到出院期间，所有患者的格拉斯哥昏迷评分（GCS）均有所改善。接受高频治疗的CMD患者的GCS中位变化值最大（比值比4.1 [1.1–16.3]，p = 0.03）。伤后12个月时，26例（26%）患者的GOS-E达到4分或以上。接受高频治疗的CMD患者在出院后6个月和12个月的GOS-E评分提升幅度较无CMD者或未接受高频治疗者更大（比值比10.7 [2.5–48.8]，p = 0.001）。
> 
> 结论：在安全方案下，ICU中可实施物理及作业治疗，且CMD患者可能对早期、高强度治疗特别敏感。未来应开展整合CMD状态的多中心研究，以确定康复干预的最佳时机与剂量，从而优化有限资源的配置。

### 第二部分 AI 大师评价

该研究探讨了重症脑损伤患者中认知运动分离（CMD）对接受早期、高频物理与作业治疗的反应性。研究采用回顾性分析与机器学习EEG检测结合的方式，创新性地将CMD状态与康复频率联系起来。结果提示CMD患者对高频治疗反应更佳，且治疗安全可行。此研究为ICU康复策略提供了依据，但受限于单中心设计与样本量较小，仍需多中心前瞻性验证。

---

## 5. 外膜囊泡疫苗可预防猕猴肺类鼻疽模型中的肺部病变

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41366245)
**期刊：** Nature communications
**PMID：** 41366245
**DOI：** 10.1038/s41467-025-67213-6

### 第一部分 原文与翻译

**英文原标题：** An outer membrane vesicle vaccine prevents lung pathology in a macaque model of pneumonic melioidosis.

> **英文摘要：**
> Melioidosis is an emerging infectious disease caused by the intracellular bacterial pathogen, Burkholderia pseudomallei. Infection of humans and animals can occur through multiple routes of bacterial entry resulting in life-threatening pneumonia and/or bacteremia. B. pseudomallei is inherently resistant to multiple antibiotics and mortality rates are high despite therapeutic intervention. Development of an effective vaccine could protect at-risk individuals, such as those who reside in highly endemic areas, military personnel, diabetics, and travelers. Despite decades of pursuit, no candidate vaccine for melioidosis has advanced beyond pre-clinical testing in rodent models. Here, we demonstrate that an outer membrane vesicle (OMV) vaccine prevents pulmonary disease in non human primates (NHP) using survivability, biotelemetry, and clinical pathology assessments. Using two independent serologic assays, we demonstrate that vaccination in rhesus macaques is associated with systemic and mucosal IgG and IgA to OMV surface proteins and polysaccharides. We also show that NHP immune sera promotes opsonophagocytosis by macrophages and that human sera responses to several key OMV antigens are associated with survival in melioidosis. Collectively, these results attest to the potential efficacy of the OMV vaccine and lay the groundwork for its advancement to human phase 1 clinical trials.

> **中文摘要：**
> 类鼻疽是一种由胞内细菌病原体假单胞菌伯克霍尔德菌（Burkholderia pseudomallei）引起的新兴传染病。人类和动物的感染可通过多种途径进入机体，导致危及生命的肺炎和/或菌血症。假单胞菌伯克霍尔德菌天然对多种抗生素具有耐药性，尽管经过治疗干预，死亡率仍然较高。开发一种有效的疫苗可保护高风险人群，例如居住在高流行地区的居民、军事人员、糖尿病患者和旅行者。尽管数十年来不断努力，但目前尚无类鼻疽候选疫苗能进入啮齿动物模型之外的临床前测试阶段。在本研究中，我们证明了一种外膜囊泡（OMV）疫苗可通过生存率、生物遥测和临床病理评估，预防非人灵长类（NHP）的肺部疾病。利用两种独立的血清学检测方法，我们发现接种猴的系统性和黏膜性IgG及IgA水平针对OMV表面蛋白和多糖均有上升。我们还显示，NHP的免疫血清可促进巨噬细胞的调理吞噬作用，而人类血清对若干关键OMV抗原的反应与类鼻疽的生存关联。总体而言，这些结果证实了OMV疫苗的潜在有效性，并为其进入人体I期临床试验奠定了基础。

### 第二部分 AI 大师评价

本研究旨在评估一种外膜囊泡疫苗在非人灵长类肺类鼻疽模型中的预防作用。研究团队通过多维病理、生理监测与免疫学分析，证明该疫苗能显著降低肺部病变，并诱导系统性与黏膜性IgG/IgA免疫应答。结果还表明免疫血清可增强巨噬细胞的吞噬功能，而人类血清中相应抗体与疾病生存相关性呈正相关。研究创新之处在于首次在灵长类模型上验证OMV疫苗对类鼻疽的保护效果，为临床转化提供了关键依据，但仍需在更大样本和临床场景中验证安全性与有效性。

---

## 6. 双胍功能化的肽模拟物有效对抗耐药性ESKAPE病原体及脑膜炎

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41365877)
**期刊：** Nature communications
**PMID：** 41365877
**DOI：** 10.1038/s41467-025-67044-5

### 第一部分 原文与翻译

**英文原标题：** Biguanide-functionalized peptide mimics effectively combat drug-resistant ESKAPE pathogens and meningitis.

> **英文摘要：**
> ESKAPE pathogens-induced meningitis seriously threatens human health due to antimicrobial resistance and low permeability of blood-brain barrier (BBB). It's a promising strategy to combat drug-resistant pathogens using synthetic mimics of host defense peptide (HDP) bearing positive charges that are mainly provided by amine or guanidine. Here, we report that biguanide serves as a type of positively charged moiety to design HDP mimics. Biguanide exerts a stronger interaction with bacterial membrane phospholipids via bidentate hydrogen bonds than do amine and guanidine. The biguanide-functionalized HDP mimic, PBGProOx, targets bacterial membrane phospholipids to show potent activity against all ESKAPE pathogens and does not induce antimicrobial resistance. PBGProOx exhibits promising BBB-penetrating property and displays potent therapeutic effects in female mice full-thickness infection model, sub-cutaneous infection model, kidney infection model, peritonitis model, and meningitis model. This study provides a promising strategy for designing HDP mimics to combat ESKAPE pathogens and meningitis.

> **中文摘要：**
> 由ESKAPE病原体引起的脑膜炎由于抗菌药物耐药性及血脑屏障（BBB）通透性低而严重威胁人类健康。利用带有正电荷的宿主防御肽（HDP）合成模拟物以对抗耐药病原体，是一种极具前景的策略，这些正电荷主要来源于胺或胍基。本文报道，双胍可作为一种正电荷基团用于设计HDP模拟物。双胍通过双齿氢键与细菌膜磷脂发生比胺和胍更强的相互作用。双胍功能化的HDP模拟物PBGProOx通过靶向细菌膜磷脂，对所有ESKAPE病原体展现出强效活性，且不诱导抗菌耐药性。PBGProOx显示出优异的BBB穿透特性，并在雌性小鼠的全层感染模型、皮下感染模型、肾脏感染模型、腹膜炎模型及脑膜炎模型中表现出显著的治疗效果。本研究为设计HDP模拟物以对抗ESKAPE病原体和脑膜炎提供了一种有前景的策略。

### 第二部分 AI 大师评价

该研究旨在开发一种基于双胍功能化的新型HDP模拟物，用于解决ESKAPE病原体导致的耐药感染及脑膜炎问题。作者在分子层面阐明了双胍与细菌膜磷脂间更强的相互作用机制，并合成了具备高效抗菌活性和良好血脑屏障穿透力的PBGProOx。研究在多种小鼠感染模型中验证了其广谱疗效和低耐药风险，体现了新的抗感染分子设计思路。其创新性在于双胍作为正电荷基团的应用与多模型验证，但仍需进一步评估其长期安全性与临床可转化潜力。

---

## 7. 联合型FXIII-C3自身抗体在自身免疫性FXIII缺乏中诱发出血与补体功能障碍

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41364521)
**期刊：** The Journal of clinical investigation
**PMID：** 41364521
**DOI：** 10.1172/JCI192619

### 第一部分 原文与翻译

**英文原标题：** Combined FXIII-C3 autoantibodies elicit bleeding and complement dysfunction in autoimmune FXIII deficiency.

> **英文摘要：**
> Autoimmune factor XIII (FXIII) deficiency is a rare hemorrhagic disease characterized by severe bleeding and a high mortality rate. However, the pathogenesis of this disease remains unclear. Currently, FXIII consumption caused by infections is becoming increasingly common. Our clinical investigation, combined with in vivo experiments, revealed that patients and mice with autoimmune FXIII deficiency displayed complement dysfunction, and that pathogenic infection and autoantibody generation were positively correlated. Further analysis revealed the presence of combined FXIII-C3 autoantibodies in patients with autoimmune FXIII deficiency. These combined autoantibodies neutralize FXIII, causing excessive bleeding, and form a complex with C3, inhibiting complement activation and complement-mediated adaptive immune responses. Therefore, compromised immune responses increase host susceptibility to pathogenic Candida albicans infections. Consequently, uncontrolled exogenous fungal infections further activate platelets and cause platelet-related CD40 ligand (CD40L) release. By interacting with the CD40 on the B cell surface, the released CD40L further promotes auto-reactive B cell activation to produce more autoantibodies, thereby forming a self-amplification loop for the progressive consumption of FXIII. We believe that this study provides a perspective on disease pathogenesis and therapeutic guidance for better treatment of autoimmune FXIII deficiency.

> **中文摘要：**
> 自身免疫性XIII因子（FXIII）缺乏症是一种罕见的出血性疾病，其特征为严重出血和高死亡率。然而，该疾病的发病机制仍不清楚。目前，由感染导致的FXIII消耗正日益常见。我们的临床研究结合体内实验表明，患有自身免疫性FXIII缺乏症的患者和小鼠均表现出补体功能障碍，且病原感染与自身抗体产生呈正相关。进一步分析发现，在自身免疫性FXIII缺乏症患者中存在联合型FXIII-C3自身抗体。这些联合抗体可中和FXIII，引发过度出血，并与C3形成复合物，抑制补体激活及补体介导的适应性免疫反应。因此，受损的免疫反应增加了宿主对致病性白色念珠菌感染的易感性。由此，难以控制的外源真菌感染进一步激活血小板并诱导血小板相关的CD40配体（CD40L）释放。释放的CD40L通过与B细胞表面的CD40相互作用，进一步促进自身反应性B细胞的激活，产生更多自身抗体，从而形成FXIII持续消耗的自我放大循环。我们认为，本研究为疾病的发病机制提供了新的视角，并为改善自身免疫性FXIII缺乏症的治疗提供了指导。

### 第二部分 AI 大师评价

该研究旨在阐明自身免疫性FXIII缺乏症的发病机制，结合临床观察与动物模型发现FXIII-C3联合自身抗体是造成出血及补体功能障碍的关键因素。研究揭示了感染、血小板活化与免疫应答失衡之间的正反馈循环，为理解疾病的自我放大病理过程提供了新思路。该工作创新性地将出血倾向与补体系统失调关联起来，为靶向抗体与免疫调节的治疗策略奠定了基础。但其机制仍需在更大样本和不同病原模型中进一步验证。

---

## 8. 在台湾，碳青霉烯类与非碳青霉烯类作为高毒力菌血症最终治疗的比较研究

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41251372)
**期刊：** Antimicrobial agents and chemotherapy
**PMID：** 41251372
**DOI：** 10.1128/aac.00846-25

### 第一部分 原文与翻译

**英文原标题：** Carbapenems versus non-carbapenems as definitive treatment for hypervirulent  bacteremia in Taiwan.

> **英文摘要：**
> Hypervirulent  (hvKp) can cause serious community-acquired pyogenic infections and is prevalent in Asian countries. Unlike classical , which is usually multidrug resistant, hvKp is usually antimicrobial-sensitive. However, the optimal definitive treatment for hvKp bacteremia remains unclear, with carbapenems often used due to severe conditions. We aimed to compare clinical outcomes of patients with hvKp bacteremia treated with carbapenems and non-carbapenems in Taiwan. This retrospective study included patients with monomicrobial hvKp bacteremia treated with appropriate definitive therapy at Taipei Veterans General Hospital from January 2015 to December 2017.  isolates carrying / genes were defined as hypervirulent strains. A multivariate logistic regression model and propensity score-matched analyses were used to identify independent risk factors for 28-day mortality. A total of 236 patients with hvKp bacteremia were identified, and 52 patients received carbapenems. The non-carbapenem group had a lower 28-day mortality than that in the carbapenem group (10.3% versus 23.1%,  = 0.016). Multivariate analysis showed definitive carbapenem therapy was not associated with 28-day mortality (OR, 1.39; 95% CI, 0.47-4.10;  = 0.549). Among 90 patients with an Acute Physiology and Chronic Health Evaluation (APACHE) II score ≥15, definitive therapy with carbapenems was still not associated with 28-day mortality (OR, 2.63; 95% CI, 0.58 to 12.00;  = 0.212). The propensity score-matched analyses yielded similar results. In conclusion, definitive carbapenem therapy for hvKp bacteremia was not associated with a survival benefit compared with non-carbapenem therapy, even in critically ill patients. The study provides valuable insights into antimicrobial stewardship in endemic regions of hvKp.

> **中文摘要：**
> 高毒力克雷伯菌（hvKp）可引起严重的社区获得性化脓性感染，并在亚洲国家广泛流行。与通常表现为多重耐药的经典克雷伯菌不同，hvKp 通常对抗菌药物敏感。然而，hvKp 菌血症的最佳最终治疗方案仍不明确，临床上因病情严重而常使用碳青霉烯类药物。本研究旨在比较台湾地区采用碳青霉烯类与非碳青霉烯类治疗 hvKp 菌血症患者的临床结局。这项回顾性研究纳入了2015年1月至2017年12月期间在台北荣民总医院接受适当最终抗菌治疗的单一菌株 hvKp 菌血症患者。携带 / 基因的分离株被定义为高毒力菌株。研究采用多变量逻辑回归模型及倾向评分匹配分析，以识别28天病死率的独立危险因素。共鉴定出236例 hvKp 菌血症患者，其中52例接受了碳青霉烯类治疗。非碳青霉烯组的28天病死率低于碳青霉烯组（10.3% 对比 23.1%，P = 0.016）。多变量分析显示，最终使用碳青霉烯类治疗与28天病死率无显著相关（比值比1.39；95%置信区间0.47–4.10；P = 0.549）。在急性生理与慢性健康评分（APACHE II）≥15的90例患者中，碳青霉烯类最终治疗仍未与28天病死率相关（比值比2.63；95%置信区间0.58–12.00；P = 0.212）。倾向评分匹配分析结果一致。总之，hvKp 菌血症患者采用碳青霉烯类最终治疗相比非碳青霉烯类并未带来生存获益，即使在重症患者中亦然。本研究为 hvKp 流行地区的抗菌药物管理提供了有价值的参考。

### 第二部分 AI 大师评价

本研究聚焦于在台湾地区高毒力克雷伯菌菌血症患者中，碳青霉烯类与非碳青霉烯类作为最终治疗的疗效比较。研究通过回顾性设计，结合多变量分析和倾向评分匹配，系统评估了两种方案与28天死亡率的关系。结果显示，碳青霉烯类治疗并未显著改善患者生存率，即便在重症亚组中亦然。该研究为抗菌药物合理使用提供证据支持，但因为回顾性设计和单中心数据，仍需进一步前瞻性研究加以验证。

---

## 9. 当前球孢子菌病治疗途径的洞见

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41251369)
**期刊：** Antimicrobial agents and chemotherapy
**PMID：** 41251369
**DOI：** 10.1128/aac.01465-25

### 第一部分 原文与翻译

**英文原标题：** Insights into current coccidioidomycosis therapeutic pathways.

> **英文摘要：**
> Coccidioidomycosis is a systemic fungal infection caused by  and , which are endemic to the Southwestern United States and parts of Mexico, Central, and South America. While oral fluconazole is widely recommended as first-line therapy, treatment failure is not uncommon for severe manifestations. This study aims to characterize antifungal treatment pathways, identify factors associated with treatment switches, and compare outcomes based on treatment courses. A retrospective cohort study was conducted using the TriNetX database with individual de-identified clinical data. Using International Classification of Diseases, Tenth Revision, Clinical Modification codes, we identified patients diagnosed with coccidioidomycosis between January 2010 and March 2024. "Treatment switches" were defined as receiving a different antifungal agent for at least three consecutive days after an initial regimen. Patient demographics, comorbidities, hospitalizations, ICU admissions, and mortality were assessed. A total of 1,909 patients met the inclusion criteria, with 1,581 having complete treatment pathway data. The majority (87.4%) began treatment with fluconazole, followed by amphotericin B (6.5%) and echinocandins (2.3%); 11.2% underwent at least one treatment switch. The most common switches were fluconazole to posaconazole (2.2%) and amphotericin B to fluconazole (1.8%). Coccidioidal meningitis patients switched from fluconazole had increased rates of ICU admission and hospitalization but similar 1-year mortality compared to fluconazole monotherapy. Fluconazole remains the first-line antifungal for coccidioidomycosis, followed by amphotericin B. Most patients required solely fluconazole treatment. While many factors are involved in therapy choice, optimization of therapeutic strategies after initial fluconazole treatment may be necessary for the future, especially for severe disease.

> **中文摘要：**
> 球孢子菌病是一种由球孢子菌属引起的系统性真菌感染，主要流行于美国西南部及墨西哥、中美洲和南美洲的部分地区。尽管口服氟康唑被广泛推荐为一线治疗药物，但在重症病例中治疗失败并不少见。本研究旨在描述抗真菌治疗路径，识别与治疗方案转换相关的因素，并基于不同治疗历程比较预后差异。本研究利用 TriNetX 数据库中的去识别化个体临床数据，开展了一项回顾性队列研究。通过国际疾病分类第十版临床修订（ICD-10-CM）编码，我们确定了2010年1月至2024年3月期间被诊断为球孢子菌病的患者。“治疗转换”被定义为在初始方案后连续至少三天接受不同抗真菌药物的情况。研究评估了患者的人口学特征、合并症、住院情况、重症监护病房（ICU）收治率以及死亡率。共有1,909名患者符合入选标准，其中1,581人具有完整的治疗路径数据。多数患者（87.4%）以氟康唑起始治疗，其次为两性霉素B（6.5%）和棘白菌素类药物（2.3%）；其中11.2%的患者经历了至少一次治疗转换。最常见的转换是氟康唑改用泊沙康唑（2.2%）以及两性霉素B改用氟康唑（1.8%）。在从氟康唑转换治疗的球孢子菌性脑膜炎患者中，ICU收治率和住院率增加，但其一年死亡率与单用氟康唑者相似。氟康唑仍为球孢子菌病首选抗真菌药物，其次为两性霉素B。大多数患者仅需氟康唑治疗。尽管治疗选择受多种因素影响，但未来或需在初始氟康唑治疗后进一步优化治疗策略，尤其针对重症病例。

### 第二部分 AI 大师评价

该研究利用大型真实世界数据库系统性分析了球孢子菌病的抗真菌治疗模式，揭示了氟康唑作为首选疗法的广泛应用及其局限性。通过比较不同药物转换的临床结果，研究发现部分严重病例在转换治疗后ICU收治率和住院率升高，但总体死亡率差异不显著。该工作为临床抗真菌治疗路径优化提供了数据支持，尤其提示在重症管理中需探索更灵活的个体化方案。研究局限于回顾性设计和数据库记录的完整性，仍需前瞻性研究进一步验证。

---

## 10. 第二代溶菌素用于感染治疗的治疗潜力

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41222983)
**期刊：** Antimicrobial agents and chemotherapy
**PMID：** 41222983
**DOI：** 10.1128/aac.01312-25

### 第一部分 原文与翻译

**英文原标题：** Second-generation lysocins as therapeutics for treating  infections.

> **英文摘要：**
> is a leading cause of nosocomial infections, including pneumonia and urinary tract infections, and the primary cause of morbidity and mortality in cystic fibrosis patients. The emergence of multidrug-resistant strains makes these infections life-threatening. To overcome this challenge, lysocins can be employed as novel antipseudomonals. Lysocins use components of the pyocin antimicrobial system to deliver bacteriophage lysins to their peptidoglycan substrate in . Peptidoglycan cleavage causes membrane destabilization, cytoplasmic leakage, and disruption of the proton motive force, thereby killing the cell. In our previous proof-of-concept study, the PyS2-GN4 lysocin killed only one-third of  strains due to the targeted receptor. This limitation can now be circumvented by engineering second-generation lysocins that bind and translocate through highly conserved -specific receptors. One lysocin, PyS5-I-GN4, uses a single domain from pyocin S5 to deliver the GN4 lysin through the conserved ferric pyochelin transporter, consequently killing 95% of multidrug-resistant clinical isolates tested. Importantly, PyS5-I-GN4 displayed antibiofilm properties and was bactericidal in serum and lung surfactant. Serum inactivation observed for lysins is not seen for lysocins, making this approach more effective for treating systemic Gram-negative bacterial infections. Despite its broadened pseudomonal strain coverage, PyS5-I-GN4 demonstrated narrow-spectrum antibacterial activity toward  only and lacked cytotoxicity toward human cells. A single dose of lysocin was protective and reduced bacteria multiple log-fold in the lungs and secondary organs in a neutropenic murine lung infection model. These findings support lysocins as therapeutics for  and provide insight into designing future constructs for other Gram-negative pathogens.

> **中文摘要：**
> 是医院感染的主要致病原因之一，包括肺炎和泌尿道感染，也是囊性纤维化患者发病率和死亡率的主要原因。多重耐药菌株的出现使这些感染具有严重的生命威胁。为克服这一挑战，可采用溶菌素作为新型抗假单胞菌药物。溶菌素利用假单胞菌素抗菌系统的组分，将噬菌体溶菌酶递送至其肽聚糖底物。肽聚糖的裂解导致细胞膜不稳定、细胞质泄漏及质子动力势破坏，从而杀灭细胞。在我们之前的概念验证研究中，PyS2-GN4 溶菌素由于靶受体的局限性，仅能杀灭约三分之一的菌株。通过工程化构建可与高度保守的特异性受体结合并穿越受体的第二代溶菌素，可克服这一限制。其中一种溶菌素 PyS5-I-GN4，利用假单胞菌素 S5 的单一结构域，通过保守的铁吡咯胆素转运蛋白递送 GN4 溶菌酶，从而杀死 95% 的多重耐药临床分离株。值得注意的是，PyS5-I-GN4 显示出抗生物膜特性，并在血清和肺表面活性物质中具有杀菌活性。针对溶菌酶在血清中失活的问题，溶菌素则不存在此现象，使其在治疗系统性革兰阴性菌感染时更为有效。尽管其覆盖了更广泛的假单胞菌株，PyS5-I-GN4 仍表现出仅针对该菌属的窄谱抗菌活性，且对人类细胞无细胞毒性。在免疫缺陷小鼠肺部感染模型中，单次给药的溶菌素具有保护作用，可使肺部及继发器官中的细菌数量下降多个对数数量级。这些结果支持溶菌素作为治疗假单胞菌感染的潜在药物，并为未来设计针对其他革兰阴性病原体的构建体提供了思路。

### 第二部分 AI 大师评价

本研究旨在开发改良版第二代溶菌素，以克服传统溶菌素受体特异性导致的抗菌谱局限。通过将噬菌体溶菌酶与假单胞菌素输送结构域整合，研究者设计出 PyS5-I-GN4，可高效经铁吡咯胆素转运系统进入细菌并杀灭多重耐药假单胞菌。该分子在体外、血清及动物模型中均表现出显著杀菌和抗生物膜能力，且无显著细胞毒性。其创新在于利用保守的细菌转运系统实现定向递送，展现出治疗革兰阴性菌感染的新方向。局限性在于仍需进一步验证其临床安全性与不同宿主内环境下的稳定性。

---

## 11. 亚胺培南-雷立巴坦在美国多重耐药性肺炎和血流感染中的疗效研究（MIRAGE）

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41201892)
**期刊：** Antimicrobial agents and chemotherapy
**PMID：** 41201892
**DOI：** 10.1128/aac.01325-25

### 第一部分 原文与翻译

**英文原标题：** Effectiveness of imipenem-relebactam for multidrug-resistant  in pneumonia and bloodstream infections in the United States (MIRAGE).

> **英文摘要：**
> Imipenem-relebactam demonstrates  activity against multidrug-resistant (MDR) , but real-world effectiveness data are limited. MIRAGE was a multicenter, retrospective, observational study of imipenem-relebactam for MDR  pneumonia and bacteremia. Patients were included if they received imipenem-relebactam for >48 h within 7 days of index  culture. The primary outcome was clinical success at day 30, defined as survival, resolution of signs and symptoms of infection, completion of intended treatment course, and absence of recurrent infection. Secondary outcomes included 30- and 90-day mortality, infection recurrence, and development of non-susceptibility. Sixty-three patients were included. Median (IQR) age was 61 (51-70) years, and the median Charlson Comorbidity Index was 5 (3-6). Forty-six percent of patients had an immunocompromising condition, 79% were in the intensive care unit, 76% were receiving mechanical ventilation, and 48% required vasopressors. Median SOFA score was 7 (5-12). Forty percent of index isolates that were tested displayed non-susceptibility to both ceftolozane-tazobactam and ceftazidime-avibactam. Fifty-six percent of patients achieved clinical success at day 30. All-cause 30- and 90-day mortality rates were 18% and 29%, respectively. Recurrent infections were documented in 37% of patients within 90 days, and resistance developed in 39% (16/41) of evaluable patients. Clinical outcomes following imipenem-relebactam for treatment of MDR  were comparable to those reported in real-world studies for other novel β-lactam agents. Our data suggests that imipenem-relebactam has a role in the treatment of patients infected with MDR .

> **中文摘要：**
> 亚胺培南-雷立巴坦对多重耐药（MDR）病原体表现出活性，但有关其真实世界疗效的数据有限。MIRAGE研究是一项多中心、回顾性、观察性研究，评估亚胺培南-雷立巴坦治疗MDR肺炎和菌血症的效果。若患者在初始培养后7天内接受亚胺培南-雷立巴坦治疗超过48小时即被纳入研究。主要结局为第30天临床成功，定义为存活、感染的体征和症状消退、完成预期疗程且无复发性感染。次要结局包括30天及90天全因死亡率、感染复发情况及耐药性发展情况。本研究共纳入63例患者，中位年龄（四分位距）为61岁（51–70），中位Charlson合并症指数为5（3–6）。46%的患者存在免疫功能受损，79%位于重症监护室，76%接受机械通气，48%需使用血管加压药物。SOFA评分中位数为7（5–12）。40%的初始菌株对头孢他啶-阿维巴坦及头孢他啶-他唑巴坦均表现为非敏感。56%的患者在第30天达到临床成功。全因死亡率在30天及90天时分别为18%和29%。在90天内，37%的患者出现感染复发；在41例可评估者中，39%（16例）发生了耐药性。总体而言，亚胺培南-雷立巴坦治疗MDR感染的临床结局与其他新型β-内酰胺类药物的真实世界研究结果相当。本研究结果提示，亚胺培南-雷立巴坦在治疗MDR感染患者中具有潜在的应用价值。

### 第二部分 AI 大师评价

该研究旨在评估亚胺培南-雷立巴坦用于治疗多重耐药病原体肺炎与血流感染的真实世界疗效。研究采用多中心回顾性设计，重点考察临床成功率、死亡率及耐药性发生。结果显示，超过半数患者在30天内取得临床成功，且死亡率与现有新型β-内酰胺药物相近。研究为亚胺培南-雷立巴坦在MDR感染治疗中的应用提供了实证依据，但样本量有限及回顾性设计可能影响结论的普适性。

---

## 12. 铁载体头孢菌素 HRS-8427 注射液在中国健康受试者中肺内穿透及药代动力学研究

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41196282)
**期刊：** Antimicrobial agents and chemotherapy
**PMID：** 41196282
**DOI：** 10.1128/aac.00702-25

### 第一部分 原文与翻译

**英文原标题：** Intrapulmonary penetration and pharmacokinetics of siderophore cephalosporin HRS-8427 injection in Chinese healthy subjects.

> **英文摘要：**
> HRS-8427, a novel siderophore cephalosporin antibiotic, is under development for treating Gram-negative infections. This study evaluated the intrapulmonary penetration and pharmacokinetic (PK) profile of HRS-8427 injection following single and multiple dose administrations in healthy Chinese subjects. A single-center, randomized, open-label Phase 1 trial enrolled 38 subjects, with 35 completing the study. In the single-dose group, subjects received a 1,500 mg intravenous infusion of HRS-8427 over 2 h. In the multiple-dose group, subjects were administered 2,000 mg of HRS-8427 intravenously every 8 h for four consecutive doses, each infused over 2 h. Bronchoalveolar lavage (BAL) was conducted to collect epithelial lining fluid (ELF) and alveolar macrophage (AM) specimens. PK analysis demonstrated a maximum plasma concentration () of 176 µg/mL and an area under the time-concentration curve from time zero to time infinity (AUC) of 942 h·μg/mL following the single 1,500 mg dose. After multiple 2,000 mg dosing, the  increased to 262 µg/mlL with a corresponding AUC of 1,640 h·μg/mL. The ELF-to-plasma concentration ratio (/) exhibited a time-dependent increase, reaching 12.2% at 8 h post-final dose. Intracellular accumulation in AM remained minimal (<1%). Multiple-dose administration resulted in higher ELF exposure than single dosing. Safety assessments indicated an overall favorable tolerability profile, with most adverse events being mild in severity. Based on PK and microbiological data, a 2,000 mg regimen achieved concentrations exceeding the MIC₉₀ values of major Gram-negative pathogens, supporting further clinical development of HRS-8427 for respiratory and other Gram-negative bacterial infections.CLINICAL TRIALSThis study is registered with Chinese Clinical Trial Registry Platform as ChiCTR2300072350.

> **中文摘要：**
> HRS-8427 是一种新型铁载体头孢菌素类抗生素，正在开发用于治疗革兰阴性菌感染。本研究评估了 HRS-8427 注射液在健康中国受试者单次及多次给药后的肺内穿透性和药代动力学特征。本为单中心、随机、开放标签的 I 期临床试验，共入组 38 名受试者，其中 35 名完成研究。在单次给药组中，受试者以 2 小时静脉输注 1,500 mg HRS-8427。在多次给药组中，受试者每 8 小时静脉输注 2,000 mg HRS-8427，共连续 4 次，每次输注 2 小时。通过支气管肺泡灌洗（BAL）采集上皮衬液（ELF）和肺泡巨噬细胞（AM）样本。药代动力学分析显示，单次 1,500 mg 给药后，血浆最大浓度为 176 µg/mL，曲线下面积（AUC₀–∞）为 942 h·μg/mL。多次 2,000 mg 给药后，最大浓度升至 262 µg/mL，对应的 AUC 为 1,640 h·μg/mL。ELF/血浆浓度比呈时间依赖性升高，在末次给药后 8 小时达到 12.2%。AM 中的细胞内累积仍较低（<1%）。多次给药较单次给药产生更高的 ELF 暴露量。安全性评估显示总体耐受性良好，大多数不良事件为轻度。基于药代动力学和微生物学数据，2,000 mg 给药方案可达到超过主要革兰阴性病原体 MIC₉₀ 的浓度，支持 HRS-8427 在呼吸道及其他革兰阴性菌感染中的进一步临床开发。本研究已在中国临床试验注册平台注册，编号为 ChiCTR2300072350。

### 第二部分 AI 大师评价

该研究系统评估了新型铁载体头孢菌素 HRS-8427 在健康受试者体内的肺部穿透性及药代动力学特征，采用单次与多次给药设计结合 BAL 检测，具有较高的研究严谨性。结果显示其在肺上皮衬液中具备良好的分布特性，多次给药后暴露量显著增强且总体耐受性较好。研究进一步证明 2,000 mg 给药方案可达到对常见革兰阴性菌有效的抑菌浓度，为后续感染性疾病临床治疗提供依据。其创新性在于探索抗生素在肺部特定区域的药物分布特征，但样本量较小及健康人群研究设计限制了临床外推性。

---

## 13. 头孢吡肟与碳青霉烯类药物在深部AmpC产生菌感染治疗中的比较：一项倾向加权回顾性队列研究

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41170947)
**期刊：** Antimicrobial agents and chemotherapy
**PMID：** 41170947
**DOI：** 10.1128/aac.00928-25

### 第一部分 原文与翻译

**英文原标题：** Comparison between cefepime and carbapenem therapy for deep-seated AmpC-producing  infections: a propensity-weighted retrospective cohort study.

> **英文摘要：**
> Deep-seated infections caused by AmpC-producing  (AmpC-E) pose challenges due to high bacterial burdens, altered pharmacokinetics, and the inoculum effect. While cefepime and carbapenems are used for bloodstream infections, their comparative effectiveness for deep-seated AmpC-E infections remains uncertain. This retrospective cohort study (2010-2023) evaluated adult inpatients with deep-seated infections caused by AmpC-E ( complex, , or ). Patients received cefepime or a carbapenem within 48 hours of index culture for ≥72 hours. Definitive therapy (high-dose cefepime or a carbapenem) was administered for ≥70% of the treatment course. The primary outcome was clinical failure, defined as (i) all-cause mortality within 30 days of index culture or (ii) infection recurrence within 30 days after completion of definitive therapy. Pooled logistic regression with inverse probability treatment weighting (IPTW) and time-varying covariates (year of therapy start, time to source control) estimated predictors of failure. Of 480 patients (cefepime  = 243, carbapenem  = 237),  complex accounted for 63.9% of infections. Unadjusted 30-day clinical failure rates were similar (14.8% for cefepime vs 11.4% for carbapenem;  = 0.267). After IPTW, carbapenem therapy had lower odds of clinical failure (adjusted odds ratio [aOR], 0.44; 95% confidence interval [CI], 0.29-0.83;  = 0.033). Intensive care unit (ICU) admission increased failure odds (aOR, 2.39; 95% CI, 1.70-3.35;  < 0.001); source control reduced them (aOR, 0.52; 95% CI, 0.40-0.68;  = 0.029). Carbapenem therapy is associated with lower adjusted odds of clinical failure than cefepime in deep-seated AmpC-E infections. ICU admission was independently associated with increased odds of clinical failure, while source control was associated with reduced odds of failure.

> **中文摘要：**
> 由AmpC产生菌（AmpC-E）引起的深部感染由于高菌负荷、药代动力学改变以及接种量效应而具有显著挑战。虽然头孢吡肟和碳青霉烯类常用于血流感染，但其在深部AmpC-E感染中的疗效比较仍不明确。本回顾性队列研究（2010–2023年）评估了因AmpC-E（复杂菌群等）导致深部感染的成年住院患者。患者在基线培养后48小时内接受至少72小时的头孢吡肟或碳青霉烯治疗。确立性治疗（高剂量头孢吡肟或碳青霉烯）在整个疗程中占比≥70%。主要结局为临床失败，定义为：（i）基线培养后30天内的全因死亡，或（ii）确立性治疗结束后30天内的感染复发。采用逆概率治疗加权（IPTW）和时间变化协变量（治疗起始年份、病灶控制时间）的汇总逻辑回归模型估计失败的预测因素。在480例患者中（头孢吡肟243例，碳青霉烯237例），复杂菌群占63.9%的感染。未校正的30天临床失败率相似（头孢吡肟14.8%，碳青霉烯11.4%，P=0.267）。IPTW调整后，碳青霉烯治疗的临床失败风险较低（调整比值比[aOR] 0.44；95%置信区间[CI] 0.29–0.83；P=0.033）。进入重症监护病房（ICU）增加失败风险（aOR 2.39；95% CI 1.70–3.35；P<0.001），而病灶控制降低失败风险（aOR 0.52；95% CI 0.40–0.68；P=0.029）。结果表明，在深部AmpC-E感染中，碳青霉烯治疗较头孢吡肟具有更低的临床失败风险；ICU入院与失败风险增加独立相关，而病灶控制与其降低相关。

### 第二部分 AI 大师评价

该研究针对深部AmpC产生菌感染这一治疗难题，比较了头孢吡肟与碳青霉烯的临床疗效。研究基于大样本回顾性队列并采用倾向加权方法，增强了结果的稳定性。结果显示碳青霉烯的治疗效果优于头孢吡肟，且病灶控制是影响预后的关键因素。研究为抗AmpC感染的治疗方案提供了重要参考，但其非随机设计及菌种分布不均仍限制因果推断的力度。

---

## 14. 套马拉车：在使用持续输注头孢托罗/他唑巴坦治疗以防止产ESBL肠杆菌耐药产生时，我们是否仍然低估了他唑巴坦剂量？

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41159735)
**期刊：** Antimicrobial agents and chemotherapy
**PMID：** 41159735
**DOI：** 10.1128/aac.01215-25

### 第一部分 原文与翻译

**英文原标题：** Keeping the horse with the cart: are we underdosing tazobactam even when using continuous-infusion ceftolozane/tazobactam for effectively preventing resistance development by ESBL-producing Enterobacterales?

> **英文摘要：**
> Ceftolozane/tazobactam is widely used against extended-spectrum β-lactamase (ESBL)-producing Enterobacterales, yet FDA-approved dosing relies on intermittent infusion and a fixed 2:1 ratio that assumes adequate β-lactamase inhibition. Tazobactam's faster and variable clearance raises concerns for subtherapeutic exposure. This study evaluated whether continuous infusion (CI) improves pharmacokinetic target attainment and whether current dosing adequately covers both components. We conducted an analysis of 139 hospitalized adults receiving CI ceftolozane/tazobactam with therapeutic drug monitoring (TDM). Free steady-state concentrations (Css) and observed clearance were calculated and assessed across kidney function strata. Population pharmacokinetic modeling and Monte Carlo simulations evaluated the probability of target attainment (PTA) for each drug. Despite kidney function-adjusted CI, 38.1% of patients had tazobactam Css <4 mg/L, a threshold linked to reduced efficacy and resistance emergence, while only 2.5% had ceftolozane Css <8 mg/L (namely 4× MIC the Enterobacterales clinical breakpoint for susceptibility). Tazobactam clearance (mean 7.41 L/h) was 2.5-fold higher than ceftolozane and highly variable (CV 115%). Kidney function explained only 23% of clearance variability. The cohort's older age (median 66 years; 26.6% ≥75 years) likely led to lower tazobactam clearance, suggesting even greater underexposure in younger patients. Simulations showed standard dosing achieved only 29%-54% cumulative response against ESBL-producing Enterobacterales, versus 73%-82% with optimized regimens using 2-3× higher ceftolozane/tazobactam doses of magnitude similar to those licensed for pneumonia. Current ceftolozane/tazobactam dosing, even with CI, is often subtherapeutic for tazobactam. These findings challenge fixed-ratio formulations and support individualized, component-guided dosing to preserve efficacy and suppress resistance.

> **中文摘要：**
> 头孢托罗/他唑巴坦广泛用于针对产超广谱β-内酰胺酶（ESBL）的肠杆菌科细菌，但FDA批准的给药方案基于间歇输注及固定的2:1比例，假设β-内酰胺酶抑制作用充足。他唑巴坦清除更快且差异较大，引发了亚治疗暴露的担忧。本研究评估持续输注（CI）是否能够改善药代动力学目标的达成率，并检验当前给药方案是否充分覆盖两种成分。我们对139名接受CI头孢托罗/他唑巴坦治疗并实施治疗药物监测（TDM）的住院成人进行了分析。计算并评估了游离稳态浓度（Css）及观察到的清除率，并按肾功能分层分析。利用群体药代动力学建模及蒙特卡洛模拟评估了每种药物的目标达成概率（PTA）。尽管根据肾功能调整了CI，仍有38.1%的患者他唑巴坦Css低于4 mg/L，该阈值与疗效下降及耐药出现相关，而仅有2.5%的患者头孢托罗Css低于8 mg/L（即肠杆菌科易感性临界MIC的4倍）。他唑巴坦清除率（平均7.41 L/h）是头孢托罗的2.5倍，且变异性很大（变异系数115%）。肾功能仅能解释清除率变异的23%。研究队列的年龄偏大（中位数66岁；26.6%年龄≥75岁）可能导致较低的他唑巴坦清除率，提示年轻患者可能存在更严重的暴露不足。模拟显示，标准剂量对产ESBL肠杆菌的累计应答仅为29%–54%，而经优化的方案使用2–3倍于标准的头孢托罗/他唑巴坦剂量（类似于用于肺炎的批准剂量）可达到73%–82%的应答。即使采用持续输注，目前的头孢托罗/他唑巴坦给药对他唑巴坦仍常为亚治疗水平。这些发现挑战了固定比例制剂，并支持基于个体化和组分导向的给药策略以维持疗效并抑制耐药。

### 第二部分 AI 大师评价

本研究针对持续输注头孢托罗/他唑巴坦治疗产ESBL肠杆菌时，他唑巴坦潜在剂量不足的问题进行了实证分析。通过对住院患者TDM数据的药代学建模及蒙特卡洛模拟，作者揭示了标准比例方案下他唑巴坦暴露不足的普遍性及其对疗效与耐药的影响。结果提示，即便持续输注也未能弥补固定2:1比例的局限，优化并个体化调整两个组分的剂量更加科学。该研究创新性地将真实世界TDM与模拟结合，揭示临床常规用法的潜在短板，但样本年龄结构可能影响推广性。

---

速递结束，祝您工作愉快！